USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/11930
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVoloc, Ana-
dc.date.accessioned2020-10-05T09:26:35Z-
dc.date.available2020-10-05T09:26:35Z-
dc.date.issued2020-
dc.identifier.citationVOLOC, Ana. The review of the products from Republic of Moldova State Medicine Nomenclature used in treatment of exocrine pancreatic insufficiency. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 284-285.en_US
dc.identifier.urihttps://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/11930-
dc.descriptionDepartment of Pharmacology and Clinical Pharmacology, Nicolae Testemițanu State University of Medicine and Pharmacy of Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020en_US
dc.description.abstractIntroduction. Exocrine pancreatic insufficiency (EPI) is characterized by maldigestion of nutrients and is caused by insufficient delivery of pancreatic digestive enzymes to the duodenum. The fact that the signs and symptoms aren’t specific, results in a late correct diagnosis and treatment. The management of EPI consists of taking digestive pancreatic enzyme medication during or immediately after the meals. The minimal dosage used when starting the therapy is between 40 000 and 50 000 USP units of lipase at each meal. An inadequate therapeutic response might be caused by the inactivation of lipase in the gastric acid if the medication doesn’t have a gastro-resistant coat. Aim of the study. To study the State Medicine Nomenclature and analyze the products suitable for treatment of EPI. Materials and methods. For this research were used: SNM, latest version including 6133 medications, international guides for gastrointestinal diseases and scientific articles. Results. Out of the 6133 products listed in the SNM, only 25 (0,4%) are drugs that contain pancreatic exocrine enzymes. From this 25: 21 (84%) contain only pancreatin, 3 (12%) – pancreatin combined with hemicellulose and bovine bile extract and 1 medication (4%) is a fusion of pancreatin, hemicellulose, bovine bile extract and simethicone. Only 6 products are with mini-microspheres, 16 have a gastro-resistant coat and 3 have an ordinary non-gastroresistant coat. According to the producing country, 52% are imported from Germany, 20% - from Ukraine, 16% - from Romania, 4% - from Turkey and only 8% are manufactured in Republic of Moldova. 5 drugs contain 25 000 USP units of lipase in each tablet/capsule, 6 products – 10 000 USP units of lipase each tablet and the other 14 medications have between 8 000 and 3 150 USP units of lipase in each pill. Currently, the following products can’t be found on the pharmaceutical market of Republic of Moldova: pancreatin + bile acids + plant extracts + antimicrobial constitutive and pancreatin + adsorbent agents. Conclusions. The diagnostic and initiation of treatment in patients with exocrine pancreatic insufficiency have to be done as soon as possible, in order to prevent the development of complications and maintain a high quality of life. The suitable drug and its dose has to be chosen for every patient individualy. The capsules with mini-microspheres seem to be the most effective from this group of medications, therefore the increase of such drugs would be welcomed on the pharmaceutical market of the country.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectexocrine pancreatic insufficiencyen_US
dc.subjectpancreatic enzyme productsen_US
dc.subjectState Medicine Nomenclatureen_US
dc.titleThe review of the products from Republic of Moldova State Medicine Nomenclature used in treatment of exocrine pancreatic insufficiencyen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2020

Files in This Item:
File Description SizeFormat 
Voloc_Ana.pdf444.14 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback